Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05818085 · ClinicalTrials.gov registry record · Phase 2
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT05818085: Completed Phase 2 study, sponsored by Atom Therapeutics Co..
NCT05818085 is a Phase 2 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05818085, a Phase 2 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Interventions
- OTHER Placebo
- DRUG Allopurinol
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 2 |
What the finished NCT05818085 record still lists
NCT05818085 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05818085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05818085 about?
NCT05818085 is a clinical study titled "Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout". This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) o...
What is the current status of trial NCT05818085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2023-08-11. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT05818085?
The interventions under investigation include: Placebo (OTHER), Allopurinol (DRUG), ABP-671 (DRUG).
Who is sponsoring clinical trial NCT05818085?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05818085's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI